Search Results

With Imaavy, J&J will go toe-to-toe with fellow Big Pharma AstraZeneca, which owns Soliris and Ultomiris.

Cerus Corporation (Nasdaq: CERS) announced today that Kevin Green, Cerus’ chief financial officer, is scheduled to participate at the 21st Annual Craig-Hallum Institution Investor Conference in Minneapolis, on Wednesday, May 29th.

Veteran oncology executive brings global development and regulatory expertise to support TCB’s life sciences strategy

Xtant Medical Holdings, Inc. today announced that Sean Browne, President and Chief Executive Officer, and Scott Neils, Chief Financial Officer, will participate in the 21st Annual Craig-Hallum Institutional Investor Conference on May 29 in Minneapolis.

Simulations Plus, Inc. (Nasdaq: SLP) (“Simulations Plus”), a leading provider of modeling and simulation solutions for the pharmaceutical, biotechnology, chemicals, and consumer goods industries, today announced that Shawn O’Connor, chief executive officer, will participate in Craig-Hallum’s 21st Annual Institutional Investor Conference on Wednesday, May 29, 2024, in Minneapolis, MN.

In the company’s first-quarter earnings call Tuesday, J&J CEO Joaquin Duato said there’s a better way to encourage drug manufacturing in the U.S. than President Donald Trump’s threatened pharma tariffs.

Inotiv, Inc. today announced that Robert Leasure Jr., President and Chief Executive Officer, and Beth Taylor, Chief Financial Officer, will participate in the upcoming 21st Annual Craig Hallum Institutional Investor Conference and Jefferies Global Healthcare Conference.

The label expansion could help J&J establish Tremfya as a successor to Stelara, which is now facing a growing biosimilar challenge.

J&J opened Q1 2025 pharma earnings Tuesday, reporting sales of $21.9 billion and diluted earnings per share of $4.54. The medicines unit provided $13.9 billion while the medtech unit generated the remaining $8 billion.